Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-059625

Dimension Therapeutics, Inc. · DMTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Period of report
Nov 7, 2017
Accepted (ET)
Nov 7, 2017 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001592288

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F1$7.08Nov 7, 2017D32,069D—May 18, 2026Common Stock32,0690D
Stock Option (Right to Buy)F2$1.15Nov 7, 2017D17,000D—May 24, 2027Common Stock17,0000D

Explanation of responses

Remarks

The Reporting Person previously reported an indirect interest in shares held directly by New Leaf Ventures III, L.P. ("NLV-III") and New Leaf Growth Fund I, L.P. ("NLGF"), with respect to which the Reporting Person disclaimed Section 16 beneficial ownership except to the extent of his/her pecuniary interest therein, if any. New Leaf Venture Associates III, L.P. ("NLVA-III") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III") is the general partner of NLVA-III. New Leaf Growth Associates I, L.P. ("NLGA") is the general partner of NLGF and NLVM-III is the general partner of NLGA. Reporting Person was employed by New Leaf Venture Partners, L.L.C. ("NLVP"), which is affiliated with the above entities. In 2016, the Reporting Person separated from NLVP and is no longer affiliated with either NLV-III or NLGF and accordingly is no longer reporting any indirect interest in the shares held directly by either NLV-III or NLGF.